NCT02683018 is a Phase 1 clinical trial of Smoked Cannabis High CBD/low THC in Chronic Pain, sponsored by New York State Psychiatric Institute.

Who is sponsoring NCT02683018?

NCT02683018 is sponsored by New York State Psychiatric Institute.

What drugs are being tested in NCT02683018?

Interventions in NCT02683018: Smoked Cannabis High CBD/low THC, Smoked Placebo Cannabis Low CBD/low THC.

What condition does NCT02683018 study?

NCT02683018 studies Chronic Pain.

Is NCT02683018 still recruiting?

NCT02683018 is currently withdrawn. Last updated 1 November 2021.

Last reviewed 2021-11-01 · How we verify

NCT02683018

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation of Cannabis for Chronic Pain and Palliative Care

Withdrawn Phase 1 Last updated 1 November 2021

What this trial tests

Phase 1 trial testing Smoked Cannabis High CBD/low THC in Chronic Pain. Withdrawn.

Timeline

Primary endpoint
28 October 2021

28 October 2021

Quick facts

Lead sponsor	New York State Psychiatric Institute
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Primary completion	28 October 2021
Estimated completion	28 October 2021

Drugs / interventions tested

Smoked Cannabis High CBD/low THC — full drug profile →
Smoked Placebo Cannabis Low CBD/low THC — full drug profile →

Conditions studied

Chronic Pain — all drugs for Chronic Pain →

Sponsor

New York State Psychiatric Institute

Who can join

Adults 21 to 60, any sex, with Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of cannabis for severe medical conditions is being legalized in different states, increasing the mandate to make cannabis legal for medically ill patients. However, there is a lack of placebo-controlled studies investigating the efficacy of cannabis. Dronabinol (synthetic, oral Δ-9-THC) is FDA approved for the appetite stimulation in AIDS-related anorexia and nausea/vomiting in chemotherapy patients. Nabilone, a synthetic analogue of THC, is approved for nausea/vomiting in chemotherapy patients. These medications have been found to be effective for these disorders, but there remains an interest in studying cannabis, partly due to the numerous cannabinoids contained within the cannabis plant. Among these is cannabidiol, which does not produce subjective effects, but has been shown to have potent anti-inflammatory effects. In addition, there is data indicating that cannabidiol may be effective for neuropathic pain and nausea/vomiting. The goal is to investigate the effects of high CBD/low THC cannabis on symptoms such as pain, nausea/vomiting, and quality of life in seriously ill participants. While there is data beginning to emerge that cannabis may have a beneficial effect on these symptoms, there are few placebo controlled, double-blind studies. Additionally, the administration of cannabis to medically ill patients may be limited by its subjective effects, such as anxiety, intoxication, or paranoia. Most cannabis available today has high levels of Δ-9-THC (about 15%). By using cannabis that is high in CBD, but low in - Δ-9-THC, it is hypothesized that some of these effects can be avoid, while maximizing the therapeutic effects, if any.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Smoked Cannabis High CBD/low THC

Trials testing the same drug.

NCT02675842 — Investigation of Cannabis for Pain and Inflammation in Lung Cancer · Phase 1 · withdrawn

Other recruiting trials for Chronic Pain

Currently open trials in the same condition.

NCT07491549 — The Effect of Pain Education Group Therapy and Its Impact on Chronic Pain, Kinesiophobia, and Physical Activity · NA · recruiting
NCT07425691 — SPACE for Youth With Chronic Pain · recruiting
NCT07103135 — Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling · Phase 1 · recruiting
NCT06219408 — CIH Stepped Care for Co-occurring Chronic Pain and PTSD · NA · recruiting
NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting

Other New York State Psychiatric Institute trials

Trials by the same sponsor.

NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02683018 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
Last refreshed: 1 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02683018.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing